TCM
RUBY

Tekla Capital Management’s Rubius Therapeutics, Inc RUBY Stock Holding History

Tekla Capital Management’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-155,982
Closed -$933K – 224
2020
Q2 		$933K Hold
155,982
– – 0.04% 196
2020
Q1 		$694K Buy
155,982
+87,609
+128% +$651K 0.03% 187
2019
Q4 		$650K Buy
+68,373
New +$661K 0.02% 188

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return

Tekla Capital Management's RUBY Position: Q3 2020 in Review

Tekla Capital Management sold out of Rubius Therapeutics, Inc (RUBY) in Q3 2020, closing a stake of 155,982 shares — an estimated $933K sold.

Tekla Capital Management first reported a position in RUBY in Q4 2019 and held it in 3 quarters. The position peaked at $933K in Q2 2020. 84 funds tracked by Wall St. Rank hold RUBY as of Q3 2020.

  • Tekla Capital Management reported no remaining Rubius Therapeutics, Inc position as of Q3 2020 after selling out during the quarter.
  • Tekla Capital Management sold 155,982 Rubius Therapeutics, Inc shares in Q3 2020, an estimated $933K.
  • Tekla Capital Management first reported a position in Rubius Therapeutics, Inc in Q4 2019 and held it in 3 quarters.
  • Tekla Capital Management's Rubius Therapeutics, Inc position peaked at $933K in Q2 2020.
  • 84 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q3 2020.

Based on Tekla Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.